Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.51 |
| ▸ | TK2 | O00142 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10178059 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL2064678 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL14680016 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL889611 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL888090 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL888088 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL12570205 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL2064682 | 1.00 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL14665814 | 0.93 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL888043 | 0.93 | TK1 (0.51) | TK1TK2LMNASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | TK1 58/4885TK2 167/4885LMNA 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.